Pneumagen logo.jpg
Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study
October 02, 2023 04:00 ET | Pneumagen Ltd
Study achieves primary & secondary endpoints in a randomised, placebo-controlled challenge studyNeumifil delivers a statistically significant reduction in both symptomatic infection rate &...
Pneumagen logo.jpg
Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections
June 01, 2023 04:00 ET | Pneumagen Ltd
Neumifil is being developed for the prevention and treatment of virus induced exacerbations in patients with respiratory diseaseAdvancing Neumifil into a Phase 2b clinical study due to start in 2024 ...
Pneumagen logo.jpg
Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent
April 18, 2023 04:00 ET | Pneumagen Ltd
Neumifil is a novel intranasal spray being developed to provide those at-risk with an easy to use, broad-spectrum antiviral treatment to reduce and prevent respiratory disease exacerbations caused by...